Abstract:We investigated the association of 5 tagging single nucleotide polymorphisms (SNPs) of MDM2 with chemotherapy-related toxicities and clinical outcomes in 663 patients with advanced non-small-cell lung cancer. We identified 2 SNPs (rs1470383 and rs1690924) with significant associations with chemotherapy-related toxicities. One SNP rs1470383 also influenced the overall survival of patients without overall toxicity or hematologic toxicity.Introduction: Platinum agents can cause the formation of DNA adducts and induce apoptosis to eliminate tumor cells. The aim of the present study was to investigate the influence of genetic variants of MDM2 on chemotherapy-related toxicities and clinical outcomes in patients with advanced non-small-cell lung cancer (NSCLC). Materials and Methods: We recruited 663 patients with advanced NSCLC who had been treated with first-line platinum-based chemotherapy. Five tagging single nucleotide polymorphisms (SNPs) in MDM2 were genotyped in these patients. The associations of these SNPs with clinical toxicities and outcomes were evaluated using logistic regression and Cox regression analyses. Results: Two SNPs (rs1470383 and rs1690924) showed significant associations with chemotherapy-related toxicities (ie, overall, hematologic, and gastrointestinal toxicity). Compared with the wild genotype AA carriers, patients with the GG genotype of rs1470383 had an increased risk of overall toxicity (odds ratio [OR], 3.28; 95% confidence interval [CI], 1.34-8.02; P = .009) and hematologic toxicity (OR, 4.10; 95% CI, 1.73-9.71; P = .001). Likewise, patients with the AG genotype of rs1690924 showed more sensitivity to gastrointestinal toxicity than did those with the wild-type homozygote GG (OR, 2.32; 95% CI, 1.30-4.14; P = .004). Stratified survival analysis revealed significant associations between rs1470383 genotypes and overall survival in patients without overall or hematologic toxicity (P = .007 and P = .0009, respectively). Conclusion: The results of our study suggest that SNPs in MDM2 might be used to predict the toxicities of platinum-based chemotherapy and overall survival in patients with advanced NSCLC. Additional validations of the association are warranted. (C) 2015 Elsevier Inc. All rights reserved.

Genetic Variants in DNA Mismatch Repair Pathway predict prognosis of Lung Cancer patients with receiving Platinum-Based Chemotherapy.

Genetic Variants in Double-Strand Break Repair Pathway Genes to Predict Platinum-Based Chemotherapy Prognosis in Patients with Lung Cancer

Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy

Role of rs873601 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy

Association Between Single Nucleotide Polymorphisms (Snps) And Toxicity Of Advanced Non-Small-Cell Lung Cancer Patients Treated With Chemotherapy

Association of variations in platinum resistance-related genes and prognosis in lung cancer patients

ASSOCIATION OF XRCC3 AND XPD751 SNP WITH RESPONSE TO PLATINUM-BASED CHEMOTHERAPY IN ADVANCED NSCLC PATIENTS

Genetic Variants of GADD45A, GADD45B and MAPK14 Predict Platinum-Based Chemotherapy-Induced Toxicities in Chinese Patients with Non-Small Cell Lung Cancer.

Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.

Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients

Genetic Variants of the MDM2 Gene Are Predictive of Treatment-Related Toxicities and Overall Survival in Patients with Advanced NSCLC.

The Association Between Genetic Polymorphisms of Transporter Genes and Prognosis of Platinum-Based Chemotherapy in Lung Cancer Patients.

Single nucleotide polymorphisms in XRCC1,XPD and platinum prognosis in non-small-cell lung cancer patients

Genetic Variants of BCL2 Gene Predict Clinical Outcomes of Non-Small-cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy in a Chinese Population.

Association Between DNA Mismatch Repair Gene Polymorphisms and Platinum-Based Chemotherapy Toxicity in Non-Small Cell Lung Cancer Patients.

Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer

Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.

Germline Genetic Variations in Drug Action Pathways Predict Clinical Outcomes in Advanced Lung Cancer Treated with Platinum-Based Chemotherapy

The Association of Genetic Variations in DNA Repair Pathways with Severe Toxicities in NSCLC Patients Undergoing Platinum-Based Chemotherapy.

Potentially functional polymorphisms in DNA repair genes and non-small-cell lung cancer survival: a pathway-based analysis.

Genetic Variants Of Nbs1 Predict Clinical Outcome Of Platinum-Based Chemotherapy In Advanced Non-Small Cell Lung Cancer In Chinese